Codon

SEPTEMBER 29, 2024

But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). It suggested that, in the future, certain classes of drugs, specifically genetic therapies, could be screened entirely virtually via models of life. As such, they were quietly abandoned.

Engineering 141

Engineering Virus DNA Therapies 141

Drug Target Review

JULY 1, 2024

Using the 10X Genomics Chromium platform, we conducted ribonucleic acid (RNA) sequencing on the midbrain’s PAG region in animals treated with SRP-001, ApAP and a vehicle control, focusing on gene expression changes related to pain processing. was founded in 2016 to develop safer, non-opioid therapies for acute and chronic pain.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Codon

MAY 15, 2023

Made from a Cas9 nickase (the histidine at amino acid position 840 is swapped for an alanine) fused to a reverse transcriptase enzyme (which makes DNA from RNA; transcription in reverse), prime editing clinical trials are expected to begin by 2025. Gene Therapy. Molecular Cell. Nature Biotechnology. Cell Systems. Cell Systems.

DNA 52

DNA Bioinformatics Engineering Virus 52

Codon

MAY 15, 2023

Made from a Cas9 nickase (the histidine at amino acid position 840 is swapped for an alanine) fused to a reverse transcriptase enzyme (which makes DNA from RNA; transcription in reverse), prime editing clinical trials are expected to begin by 2025. Gene Therapy. Molecular Cell. Nature Biotechnology. Cell Systems. Cell Systems.

DNA 52

DNA Bioinformatics Engineering Virus 52

SugarCone Biotech

APRIL 8, 2025

Astra Zenecas purchase of Esobiotec with a $425M upfront has rekindled interest in CAR-T cell therapy technologies, and in particular, the in vivo cell therapy companies. In vivo CAR-T cell therapy requires that genetic material be delivered to the desired immune cells while those cells are still inside the patient.

Therapies 57

Therapies RNA Packaging Engineering 57

Elrig

MARCH 10, 2025

Research & Innovation 2025 Keynote Speakers Announced Cambridge, UK, 24 January 2025: The European Laboratory Research & Innovation Group (ELRIG), a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Research & Innovation 2025.

Research 52

Research Laboratories Medical Schools Engineering 52

Drug Target Review

APRIL 1, 2025

Advances in biotechnology are driving significant progress in the treatment of rare diseases, making it possible to develop targeted therapies for previously untreatable conditions. Founded in 2021, SynaptixBio is working to develop therapies for TUBB4A leukodystrophies – a group of rare and severe neurological disorders.

Disease 52

Disease Therapies Clinical Trials Cell Biology 52

Broad Institute

JANUARY 27, 2025

A genome-wide atlas of cell morphology reveals gene functions By Allessandra DiCorato January 27, 2025 Breadcrumb Home A genome-wide atlas of cell morphology reveals gene functions PERISCOPE, a technique for genome-wide imaging screens, is helping Broad scientists understand the connections between genes and traits. Online January 27, 2025.

DNA 131

DNA RNA Science Research 131

Broad Institute

JANUARY 16, 2025

By Allessandra DiCorato January 16, 2025 Credit: Scott Sassone, Broad Communications Tara McDonald (left) and Steve McCarroll (right) are coauthors of a new paper describing a biological mechanism underlying Huntington's disease. Online January 16, 2025. Funding This work was supported by CHDI Foundation, Inc., DOI: 10.1016/j.cell.2024.11.038.

Disease 130

Disease DNA Medical Schools RNA 130

keypoint

JANUARY 8, 2025

Our first Fellows Spotlight of 2025 goes to Keystone Symposia Fellow Dr. Abigael Cheruiyot! Studying RNA surveillance mechanisms, they identified nonsense mediated decay as a potential target for novel cancer therapies. She is very passionate about both science and promoting equity within the research community.

Medical Schools 59

Medical Schools RNA Laboratories Doctors 59

Drug Target Review

DECEMBER 16, 2024

Since their first approvals in 2017, autologous CAR T-cell therapies have revolutionised the treatment of blood cancers, offering hope where previous options had failed. Consequently, these therapies come with significant burdens and are often underutilised despite their transformative patient outcomes.

Therapies 52

Therapies Clinical Trials Treatment Trials 52

Codon

FEBRUARY 19, 2025

ESM is a protein language model that captures certain aspects of protein structure and function, for example, but is blind to DNA or RNA-level features that drive cell behavior. Evo 2 was trained on DNA sequences but can make predictions about myriad aspects of biology, including RNA stability and protein structures. & McCarty N.

DNA 99

DNA Laboratories Engineering RNA 99

Drug Target Review

NOVEMBER 27, 2024

For example, the European Medicines Agency (EMA), in its Regulatory Science Strategy to 2025 , has highlighted the critical role of biomarker discovery, qualification and utilisation in accelerating precision medicine.

Drug Development 52

Drug Development Regulations Laboratories FDA 52

Codon

FEBRUARY 5, 2025

The researchers also ran follow-up experiments in the laboratory; cell lines carrying the same mutations as those found in the monkey had similar RNA expression patterns as cells taken from Parkinson’s patients. ” Asimov Press (2025). If you’re interested, please contact him at trevor[at]highwaypharm.com.

Disease 52

Disease Treatment Research RNA 52

Codon

FEBRUARY 23, 2025

After decades of research into therapies and preventive measures, though, global AIDS deaths have now fallen to about 600,000 annually. In January 2025, the incoming Trump administration issued a 90-day freeze on PEPFAR while it conducts a “programmatic efficiencies” review. ” Asimov Press (2025).

Clinical Trials 68

Clinical Trials Virus Vaccine DNA 68